- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07834047
Acupuncture for Post-traumatic Olfactory Dysfunction: A Randomized Controlled Trial
The goal of this clinical trial is to learn if acupuncture based on the "Form-Qi-Spirit" theory works to treat post-traumatic olfactory dysfunction in adults. It will also learn about the safety of this acupuncture treatment.
The main questions it aims to answer are:
Is the efficacy of 4-week acupuncture treatment superior to 4-week steroid treatment for post-traumatic olfactory dysfunction?
What medical problems or side effects do participants have when receiving acupuncture?
Researchers will compare real acupuncture plus a placebo (a look-alike pill with no active drug) to sham acupuncture (non-penetrating placebo needles) plus low-dose oral steroids (prednisone) - to see if the real acupuncture strategy works better than the steroid strategy for post-traumatic olfactory dysfunction.
Participants will:
Receive real acupuncture + placebo pills, OR sham acupuncture + low-dose prednisone, for 4 weeks
Undergo acupuncture/sham sessions 3 times per week (12 sessions in total)
Take the assigned pills daily (with tapering doses over 4 weeks)
Visit the clinic for smell tests, psychological assessments, and safety checks at baseline, at 4 weeks (end of treatment), and at 12 weeks (8 weeks after treatment ends)
Let me know if you need a more detailed version or any adjustments.
Panoramica dello studio
Stato
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Huanqin Li, Doctor
- Numero di telefono: 0086+13521663936
- Email: hqin_li@163.com
Backup dei contatti dello studio
- Nome: Ruotong Zhao, Master
- Numero di telefono: 0086+17701054857
- Email: 3380884776@qq.com
Luoghi di studio
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Cina, 100070
- Beijing Tiantan Hospital
-
Investigatore principale:
- Huanqin Li
-
Sub-investigatore:
- Xiaoyu Yan
-
Sub-investigatore:
- Qian Liu
-
Sub-investigatore:
- Mingyang Cao
-
Contatto:
- Li Huanqin Li
- Numero di telefono: 13521663936
- Email: hqin_li@163.com
-
Contatto:
- Huanqin Li
- Numero di telefono: 0086+13521663936
- Email: hqin_li@163.com
-
Sub-investigatore:
- Weiming Liu
-
Sub-investigatore:
- Hao Shen
-
Sub-investigatore:
- Ruotong Zhao
-
Sub-investigatore:
- Yunfei Li
-
Sub-investigatore:
- Mingxing Zhang
-
Sub-investigatore:
- Keren He
-
Sub-investigatore:
- Yukun Liang
-
Sub-investigatore:
- Jincun Lai
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Patients with post-traumatic olfactory dysfunction who meet the diagnostic criteria;
- Aged 18-60 years;
- Subjects who have given informed consent and voluntarily participate and sign the informed consent form;
- Have not received acupuncture treatment, olfactory disorder-related medications (such as intranasal corticosteroids or oral drugs), or olfactory training within the past 1 month;
- Are in a stable post-traumatic condition without severe complications, and are able to cooperate with diagnosis, treatment, and evaluation.
Exclusion Criteria:
- Patients with a clear history of viral infection or exposure to irritant substances prior to the onset of olfactory dysfunction;
- History of nasopharyngeal tumor, or presence of active nasal diseases (sinusitis, nasal polyposis, atrophic rhinitis, allergy), as well as severe nasal obstruction caused by nasal stenosis or deformity;
- History of chemotherapy or treatment with estrogen inhibitors (aromatase inhibitors), or prior use of medications known to be harmful to olfactory function before the onset of olfactory dysfunction;
- Patients with cognitive impairment and neurodegenerative diseases (Alzheimer's disease and Parkinson's disease), or severe psychiatric disorders (e.g., schizophrenia, bipolar disorder, olfactory hallucinations);
- Current use of medications that may affect olfaction (e.g., antidepressants and antihistamines);
- Allergy to prednisone;
- Pregnant or lactating women.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore attivo: Treatment arm
The treatment group includes two interventions: acupuncture and a steroid placebo (prednisone placebo). Acupoint selection: Fengchi (GB20, bilateral, quick needling), Jingbailao (bilateral, quick needling), Dazhuipang (bilateral, quick needling); Shenting (DU24), Baihui (DU20), Yingxiang penetrating Bitong (bilateral), Quanliao penetrating Bitong (bilateral), Hegu (LI4, bilateral), Wailaogong (bilateral), Zusanli (ST36, bilateral), Taichong (LR3, bilateral). Procedure: First, the patient sits upright. Quick needling (without retaining needles) is performed at Fengchi, Jingbailao, and Dazhuipang. Then, the patient assumes a supine position. Needles are inserted Shenting, Baihui, etc.while deep needling is performed at Yingxiang penetrating Bitong, Quanliao penetrating Bitong, Hegu, and Zusanli. After achieving deqi (needle sensation), the needles are retained for 20 minutes. Course: 3×/week for 4 weeks (12 sessions). Oral prednisone placebo at same dose/duration as control group. |
Acupoint selection: Fengchi (GB20, bilateral, quick needling), Jingbailao (bilateral, quick needling), Dazhuipang (bilateral, quick needling); Shenting (DU24), Baihui (DU20), Yingxiang penetrating Bitong (bilateral), Quanliao penetrating Bitong (bilateral), Hegu (LI4, bilateral), Wailaogong (bilateral), Zusanli (ST36, bilateral), Taichong (LR3, bilateral). Procedure: The patient is first seated upright. Quick needling (without needle retention) is performed at Fengchi, Jingbailao, and Dazhuipang. Then the patient assumes a supine position. Needles are inserted at Shenting, Baihui, Wailaogong, and Taichong, while deep needling is applied at Yingxiang penetrating Bitong, Quanliao penetrating Bitong, Hegu, and Zusanli. After achieving deqi (needle sensation), the needles are retained for 20 minutes. Course of treatment: Acupuncture is given 3 times per week for 4 weeks (total 12 sessions) The placebo tablets were manufactured to be identical in appearance (color, size, shape) and taste to the active prednisone tablets, ensuring effective blinding. Participants received the placebo orally according to the same tapering regimen as the control group: 30 mg/day (as equivalent tablet count) for week 1, 15 mg/day for week 2, 10 mg/day for week 3, and 5 mg/day for week 4, after which the medication was discontinued. The total course lasted 4 weeks, matching the duration of both the active prednisone therapy and the acupuncture sessions. |
|
Comparatore attivo: control arm
Medication: Oral prednisone given as a short-term course (4 weeks). Dosage and tapering schedule: Week 1: 30 mg/d; Week 2: 15 mg/d; Week 3: 10 mg/d; Week 4: 5 mg/d, then discontinued after 4 weeks. Sham acupuncture: Park sham acupuncture device (placebo needle) is used. The acupoint selection and operation sites are the same as those in the treatment group. After routine disinfection, the needle holder is applied to the acupoint, and the needle is inserted into the holder without penetrating the skin, and retained for 20 minutes. The treatment course is the same as the treatment group (3 times per week for 4 weeks). |
Oral prednisone given as a short-term course (4 weeks). Dosage and tapering schedule: Week 1: 30 mg/d; Week 2: 15 mg/d; Week 3: 10 mg/d; Week 4: 5 mg/d, then discontinued after 4 weeks. Sham acupuncture: Park sham acupuncture device (placebo needle) is used. The acupoint selection and operation sites are the same as those in the treatment group. After routine disinfection, the needle holder is applied to the acupoint, and the needle is inserted into the holder without penetrating the skin, and retained for 20 minutes. The treatment course is the same as the treatment group (3 times per week for 4 weeks). |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Improvement rate of the CSIT score at 4 weeks
Lasso di tempo: From enrollment to the end of treatment at 4 weeks
|
Improvement rate of the CSIT score at 4 weeks.The olfactory identification test is the Chinese Smell Identification Test (CSIT), developed by the Human Olfaction Laboratory, Institute of Psychology, Chinese Academy of Sciences, based on the Chinese population. It contains 40 odor items familiar to the Chinese population and has a 6-month test-retest reliability of 0.92.If the CSIT score improves by 4 points or more, this indicates an improvement in olfactory function. |
From enrollment to the end of treatment at 4 weeks
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Improvement rate of the CSIT score at 12 weeks
Lasso di tempo: at 12 weeks after enrollment
|
Rate of improvement in olfactory identification test scores after 12 weeks,The olfactory identification test is the Chinese Smell Identification Test (CSIT), developed by the Human Olfaction Laboratory, Institute of Psychology, Chinese Academy of Sciences, based on the Chinese population. It contains 40 odor items familiar to the Chinese population and has a 6-month test-retest reliability of 0.92.If the CSIT score improves by 4 points or more, this indicates an improvement in olfactory function. |
at 12 weeks after enrollment
|
|
olfactory threshold scores
Lasso di tempo: From enrollment to the end of treatment at 4 weeks;12 weeks after enrollment
|
It measures the lowest concentration level that the patient can perceive, assessing sensitivity in detecting odors. It targets the peripheral olfactory nerves. It includes 20 concentration-graded odor sticks (of the same odor) and a baseline odor stick (nearly odorless). The patient smells one graded odor stick and one baseline odor stick sequentially and compares which odor is stronger. |
From enrollment to the end of treatment at 4 weeks;12 weeks after enrollment
|
|
subjective olfactory function
Lasso di tempo: From enrollment to the end of treatment at 8 weeks;12 weeks after enrollment
|
The visual analogue scale (VAS, 0-100) in the olfactory disorder scale was used to rate the severity of olfactory loss, where 0 indicates normal olfaction and 100 indicates complete loss of smell. According to other published studies, the severity of olfactory loss was categorized as mild (0-30), moderate (31-70), and severe (>70). |
From enrollment to the end of treatment at 8 weeks;12 weeks after enrollment
|
|
Emotional and psychological assessment
Lasso di tempo: From enrollment to the end of treatment at 8 weeks;12 weeks after enrollment
|
Emotional and psychological assessment will be conducted using the Hamilton Anxiety Scale (HAMA), the 17-item Hamilton Depression Scale (HAMD17), the Generalized Anxiety Disorder 7-item scale (GAD-7), and the Patient Health Questionnaire-9 (PHQ-9) to evaluate patients' emotional and psychological status. |
From enrollment to the end of treatment at 8 weeks;12 weeks after enrollment
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Adverse events
Lasso di tempo: From enrollment to the end of observation at 12 weeks
|
Adverse events within 12 weeks after randomization, such as infection, pain, and other acupuncture-related complications in the Traditional Chinese Medicine Department; major adverse events will be reported until the end of the study. |
From enrollment to the end of observation at 12 weeks
|
Collaboratori e investigatori
Sponsor
Investigatori
- Cattedra di studio: Huanqin Li, Beijing Tiantan Hosital
Studiare le date dei record
Studia le date principali
Inizio studio (Stimato)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- KY2026-208-02
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Yes We plan to publish a protocol of this trial in about 6-8 months after the registration, and one paper of the trial including results in a high-impact peer reviewed journal in one year after the trial. About two years after the end of this trial and our open publication of the result, the primary data and type of analysis will be available for 5-10 years until data updated by a more specific study with larger number of participants. Anyone who are interested in the trial can ask us to share the primary data by send a requirement through email. We provide the collected primary data without no real information of participants, all the data sequence will be numbered instead of real names.
Periodo di condivisione IPD
About two years after the end of this trial and our open publication of the result, the primary data and type of analysis will be available for 5-10 years until data updated by a more specific study with larger number of participants.
Criteri di accesso alla condivisione IPD
Anyone who are interested in the trial can ask us to share the primary data by send a requirement through email.
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- RSI
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .